Loading clinical trials...
Loading clinical trials...
Browse 5,960 clinical trials for multiple sclerosis. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 2181-2200 of 5,960 trials
NCT06195644
This study will be conducted to investigate the following: 1. The impact of implementing GVS in MS rehabilitation on cortical excitability. 2. The influence of GVS on upper limb function in patients diagnosed with MS. Patients will be randomly assigned to a control group (Conventional Physical Therapy program = CPT) and a study group (Galvanic Vestibular Stimulation = GVS in addition to the conventional program) subsequently. CPT will perform moderate intensity aerobic training (arm ergometer) and task oriented hand manipulation training, while GVS will receive Galvanic Vestibular Stimulation will be added to the conventional physical Therapy program.
NCT02900287
Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.
NCT03858166
This study is a multicenter, open-label, randomized clinical trial. Patients with ovarian cancer receiving postoperative adjuvant chemotherapy were eligible to enroll in this study. Eligible patients were randomly allocated in a "1:1" to "Standard group" ( 6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy) and "Adjusted group" (6mg PEG-rhG-CSF was administrated subcutaneously when ANC \< 1000/mm3 after chemotherapy). All patients need to receive at least 2 cycles of PEG-rhG-CSF administration. The primary outcome is the incidence of grade 3/4 neutropenia, and the duration of grade 3/4 neutropenia, the second outcomes are the incidence of FN, neutropenia-related hospitalization, incidence of reduction and delay of chemotherapy dose and safety of PEG-rhG-CSF.